{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:30:32Z","timestamp":1792801832553,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.semnuclmed.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:50:46Z","timestamp":1764593446000},"page":"173-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is There a Role of FAPI Pet in Renal and Bladder Cancer?"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C. Luna","family":"Mass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-8883","authenticated-orcid":false,"given":"Esra","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-9606","authenticated-orcid":false,"given":"G\u00f6ksel","family":"Al\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4367","authenticated-orcid":false,"given":"Priscilla","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-9488","authenticated-orcid":false,"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0001","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/cancers7040902","article-title":"Cancer-associated fibroblasts: their characteristics and their roles in tumor growth","volume":"7","author":"Shiga","year":"2015","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0003","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/life13091821","article-title":"Head-to-head comparison of FDG and radiolabeled FAPI PET: a systematic review of the literature","volume":"13","author":"Guglielmo","year":"2023","journal-title":"Life"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0004","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0006","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","article-title":"177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review","volume":"55","author":"Al-Ibraheem","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-019-04490-6","article-title":"An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious\/inflammatory disorders","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0008","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study","volume":"34","author":"Dabestani","year":"2016","journal-title":"World J Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00259-015-3159-6","article-title":"Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET\/CT","volume":"43","author":"Alongi","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40336-024-00647-y","article-title":"99mTc]Tc-sestamibi for the differential diagnosis of renal masses: a study protocol","volume":"12","author":"Urso","year":"2024","journal-title":"Clin Transl Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.euf.2018.08.004","article-title":"The role of radiolabeled prostate-specific membrane antigen positron emission tomography\/computed tomography for the evaluation of renal cancer","volume":"6","author":"Evangelista","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0012","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RLU.0000000000004151","article-title":"Metastasis from clear cell renal cell carcinoma mimicking well-differentiated pancreatic neuroendocrine tumor at 18F-FDG and 68Ga-DOTATOC PET\/CT","volume":"47","author":"Guglielmo","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/wjnm.WJNM_38_17","article-title":"Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: three case reports and a review of the literature","volume":"17","author":"Nadebaum","year":"2018","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0014","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/RLU.0000000000000351","article-title":"Molecular imaging of late somatostatin receptor\u2013positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET\/CT","volume":"39","author":"Peter","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/jpm13030512","article-title":"Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence","volume":"13","author":"Barone","year":"2023","journal-title":"J Pers Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0017","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.12998\/wjcc.v11.i36.8447","article-title":"Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer","volume":"11","author":"\u00d6zt\u00fcrk","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0018","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/ph18050701","article-title":"Comparison of PERCIST5, imPERCIST5, and PERCIMT criteria for early assessment of pembrolizumab response with FDG-PET\/CT in metastatic bladder cancer patients","volume":"18","author":"Bertaux","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0019","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/bco2.304","article-title":"Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial\/bladder cancer","volume":"5","author":"Al-Zubaidi","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0020","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3390\/cancers15112951","article-title":"Assessing the performance of 18F-FDG PET\/CT in bladder cancer: a narrative review of current evidence","volume":"15","author":"Bacchiani","year":"2023","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s43046-023-00180-5","article-title":"Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience","volume":"35","author":"Shahait","year":"2023","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0023","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","article-title":"Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers","volume":"91","author":"Scanlan","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0024","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1074\/jbc.M115.701433","article-title":"Fibroblast Activation Protein (FAP) accelerates collagen degradation and clearance from lungs in mice","volume":"291","author":"Fan","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0025","article-title":"Decoding tumors from fibroblast activation protein: a review of the latest diagnostic and therapeutic prospects","volume":"318","author":"Wang","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0026","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3892\/mmr.2015.3259","article-title":"Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma","volume":"11","author":"Patsouras","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157399","article-title":"Targeting FAP\u03b1-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models","volume":"132","author":"Qi","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0028","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial\u2013mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0029","doi-asserted-by":"crossref","first-page":"23282","DOI":"10.18632\/oncotarget.7818","article-title":"Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0030","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.17538","article-title":"MM-BMSCs induce na\u00efve CD4+ T lymphocytes dysfunction through fibroblast activation protein \u03b1","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0031","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms24043863","article-title":"Fibroblast activation protein inhibitor (FAPI)-based theranostics\u2014where we are at and where we are heading: a systematic review","volume":"24","author":"Sidrak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0032","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging\u2014an updated review","volume":"13","author":"Chandekar","year":"2023","journal-title":"Diagnostics"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0033","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-024-06807-6","article-title":"[64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00299-2","article-title":"68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","author":"Pabst","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.122.264494","article-title":"Fibroblast activation protein\u2013targeted radioligand therapy for treatment of solid tumors","volume":"64","author":"Lindeman","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/13543784.2024.2414119","article-title":"Theranostic strategies in sarcoma: preliminary clinical evidence","volume":"33","author":"Filippi","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0037","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","article-title":"Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice","volume":"51","author":"Taddio","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0038","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","article-title":"177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma","volume":"47","author":"Kaghazchi","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0039","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0040","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0041","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/ph18040522","article-title":"Fibroblast activation protein inhibitor (FAPI)-based theranostics","volume":"18","author":"Serumula","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0042","first-page":"11","article-title":"The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases","author":"Errarte","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113393","article-title":"Altered tissue and plasma levels of fibroblast activation protein-\u03b1 (FAP) in renal tumours","volume":"12","author":"Solano-Iturri","year":"2020","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0044","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","article-title":"New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0045","first-page":"74","article-title":"Spatial expression of fibroblast activation protein-\u03b1 in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment","author":"Larrinaga","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0046","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1442-2042.2002.00416.x","article-title":"Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer","volume":"9","author":"Miyakita","year":"2002","journal-title":"Int J Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0047","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1021\/acs.molpharmaceut.5c00464","article-title":"Structural optimization of fibroblast activation protein inhibitors through Zwitterionic and PEG modification strategy: impact on pharmacokinetics and tumor imaging","volume":"22","author":"Yuan","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0048","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/bjr\/tqae025","article-title":"A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET\/CT in renal cell carcinoma","volume":"97","author":"Guo","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0049","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0050","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0051","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.7150\/thno.113070","article-title":"Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG\/[18F]AlF-NOTA-FAPI-04 PET\/CT in renal cell carcinoma","volume":"15","author":"Gao","year":"2025","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0052","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.2967\/jnumed.123.266007","article-title":"Tumor-targeted interleukin 2 boosts the anticancer activity of FAP-directed radioligand therapeutics","volume":"64","author":"Galbiati","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0053","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0054","article-title":"FAP-targeted radioligand therapy with 68 Ga\/177 Lu-DOTA-2P(FAPI) 2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3556","article-title":"FN1 and cancer-associated fibroblasts markers influence immune microenvironment in clear cell renal cell carcinoma","volume":"25","author":"Ashok","year":"2023","journal-title":"J Gene Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0056","first-page":"23","article-title":"FAP promotes clear cell renal cell carcinoma progression via activating the PI3K\/AKT\/mTOR signaling pathway","author":"Jiang","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0057","article-title":"Head-to-head comparison of 68Ga-FAPI PET\/CT and 18F-FDG PET\/CT in fumarate hydratase-deficient renal cell carcinoma","author":"Huang","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000004607","article-title":"68Ga-FAPI-04 PET\/CT in a small sarcomatoid renal cell carcinoma with widespread metastases","volume":"48","author":"Dong","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0059","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00259-023-06461-4","article-title":"The role of [68 Ga]Ga-FAPI-04 PET\/CT in renal cell carcinoma: a preliminary study","volume":"51","author":"Civan","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0060","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0061","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68 Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0062","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43046-022-00145-0","article-title":"Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics","volume":"34","author":"Abd El-Azeem","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0063","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2023.02.011","article-title":"Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities","volume":"6","author":"Caramelo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0064","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0065","article-title":"Fibroblast activation protein identifies progressive bladder cancer and allows peritoneal metastasis detection by 68Ga-FAPI PET\/CT imaging \u2013 a case report","volume":"8","year":"2024","journal-title":"J Med Imaging Case Rep"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0066","article-title":"99mTc-FAPI uptake in a rare case of metastatic urachal carcinoma","volume":"43","author":"Sahafi","year":"2024","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0067","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"68 Ga]Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0068","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00259-025-07239-6","article-title":"68Ga-FAPI and 18F-FAPI PET\/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0069","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001109748.46743.aa.16","article-title":"MP05-16\u2003prospective evaluation of [68GA]-FAPI-PET\/MRI for loco-regional staging of muscle-invasive bladder cancer","volume":"213","author":"Laukhtina","year":"2025","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0070","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0071","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.123.266652","article-title":"Diagnostic accuracy of 68 Ga-FAPI versus 18 F-FDG PET in patients with various malignancies","volume":"65","author":"Hirmas","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0072","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial experience with 68 Ga-FAP-2286 PET imaging in patients with urothelial cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0073","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2967\/jnumed.122.264941","article-title":"Three-time-point PET analysis of 68 Ga-FAPI-46 in a variety of cancers","volume":"64","author":"Naeimi","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0074","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0075","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/RLU.0000000000004865","article-title":"177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions","volume":"48","author":"Li","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0076","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40291-024-00735-9","article-title":"Is there a role for FAPI PET in urological cancers?","volume":"28","author":"Ortolan","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1053\/j.semnuclmed.2025.11.003_bib0077","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1007\/s00330-023-09715-9","article-title":"68Ga- or 18F-FAPI PET\/CT\u2014what it can and cannot","volume":"33","author":"Mori","year":"2023","journal-title":"Eur Radiol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:49:26Z","timestamp":1773845366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0001299825001576"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Role of FAPI Pet in Renal and Bladder Cancer?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}